Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
215 hedge funds and large institutions have $2.06B invested in Genomic Health, Inc. in 2019 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 95 increasing their positions, 71 reducing their positions, and 62 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 71
14% more call options, than puts
Call options by funds: $2.02M | Put options by funds: $1.77M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less capital invested
Capital invested by funds: $2.51B → $2.06B (-$449M)
19% less funds holding
Funds holding: 267 → 215 (-52)
76% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 62
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$31M |
| 2 |
State Street
Boston,
Massachusetts
|
+$28.4M |
| 3 |
Renaissance Technologies
New York
|
+$25.8M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$25.8M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$18.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$55.6M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$28.4M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$18.7M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$13.6M |
| 5 |
Robeco Institutional Asset Management
Rotterdam,
Netherlands
|
-$11.1M |
GHDX Hedge Fund Activity: Q2 2019 in Review
215 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q2 2019, worth a combined $2.06B — down 18% from $2.51B a quarter earlier.
Sellers outnumbered buyers: 62 funds closed out of GHDX and 15 opened new positions — a net loss of 47 holders — while 71 trimmed existing stakes and 95 added.
The largest buyer was Invesco, adding an estimated $31M. The largest seller was Baker Bros. Advisors, cutting an estimated $55.6M.
- 215 institutional investors held Genomic Health, Inc. (GHDX) as of Q2 2019, down from 267 in Q1 2019.
- Funds reported $2.06B of Genomic Health, Inc. stock for Q2 2019, down 18% quarter-over-quarter.
- 15 funds opened new Genomic Health, Inc. positions in Q2 2019 and 62 closed out, a net change of -47 holders.
- The largest Genomic Health, Inc. buyer in Q2 2019 was Invesco, an estimated $31M added.
- The largest Genomic Health, Inc. seller in Q2 2019 was Baker Bros. Advisors, an estimated $55.6M sold.
Based on aggregated 13F filings for Q2 2019.